Abstract
The transcription factors c-Myc and E2F-1 have been shown to harbour both mitogenic and apoptotic properties. Both factors have been implicated in the regulation of the transition from the G1 phase to the S phase in the mammalian cell cycle. However, whether cell death triggered by these molecules is dependent on the cell's position in the ongoing cell cycle remained elusive. Using centrifugal elutriation we here show for the first time that c-Myc induces apoptosis in G1 and in G2 phase, whereas E2F-1-induced apoptosis specifically occurs in G1. S phase cells are resistant to cell death triggered by these factors. We demonstrate that this is not a general phenomenon, since S phase cells are susceptible to apoptosis induced by treatment with actinomycin D and to the anti-apoptotic activity of Bcl-2. Our data indicate that S phase cells harbour specific protective activities against c-Myc- and E2F-1-induced apoptosis. Our results demonstrate that these transcription factors, although probably sharing specific apoptotic pathways, also take distinct routes to induce cell death and that apoptosis can occur at different phases of the cell cycle depending on the apoptotic stimulus. In this report we present the usefulness of a new approach to determine the regulation of apoptosis in the ongoing unperturbated cell cycle. This approach has clear implications for the identification of target genes involved in the regulation of cell death.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Askew DS, Ashmun RA, Simmons BC and Cleveland JL. . 1991 Oncogene 6: 1915–1922.
Bouchard C, Staller P and Eilers M. . 1998 Trends Cell Biol. 8: 202–206.
Borner C. . 1996 J. Biol. Chem. 271: 12695–12698.
Dao T, Huleatt JW, Hingorani R and Crispe IN. . 1997 J. Immunol. 159: 4261–4267.
Eilers M, Picard D, Yamamoto KR and Bishop JM. . 1989 Nature 340: 66–68.
Evan GI, Brown L, Whyte M and Harrington E. . 1995 Curr. Opin. Cell. Biol. 7: 825–834.
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC. . 1992 Cell 69: 119–128.
Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, Orkin SH and Greenberg ME. . 1996 Cell 85: 549–561.
Galaktionov K, Chen X and Beach D. . 1996 Nature 382: 511–517.
Harrington EA, Bennett MR, Fanidi A and Evan GI. . 1994 EMBO J. 13: 3286–3295.
Hateboer G, Kerkhoven RM, Shvarts A, Bernards R and Beijersbergen RL. . 1996 Genes Dev. 10: 2960–2970.
Helin K. . 1998 Curr. Opin. Gen. Dev. 8: 28–35.
Hengstschläger M, Pusch O, Soucek T, Hengstschläger-Ottnad E and Bernaschek G. . 1997 BioTechniques 23: 232–237.
Hofmann F, Martelli F, Livingston DM and Wang Z. . 1996 Genes Dev. 10: 2949–2959.
Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K and Lu X. . 1997 Genes Dev. 11: 1840–1852.
Hueber A-O, Zörnig M, Lyon D, Suda T, Nagata S and Evan GI. . 1997 Science 278: 1305–1309.
Kowalik TF, DeGregori J, Schwarz JK and Nevins JR. . 1995 J. Virol. 69: 2491–2500.
Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI. . 1995 Nucl. Acids Res. 23: 1686–1690.
Packham G, Porter CW and Cleveland JL. . 1996 Oncogene 13: 461–469.
Phillips AC, Bates S, Ryan KM, Helin K and Vousden KH. . 1997 Genes Dev. 11: 1853–1863.
Pusch O, Bernaschek G, Eilers M and Hengstschläger M. . 1997 Oncogene 15: 649–656.
Qin X-Q, Livingston DM, Kaelin WG and Adams PD. . 1994 Proc. Natl. Acad. Sci. USA 91: 10918–10922.
Reed JC. . 1996 Behring Inst. Mitt. 97: 72–100.
Rudolph B, Zwicker J, Saffrich R, Henglein B, Müller R, Ansorge W and Eilers M. . 1996 EMBO J. 15: 3065–3076.
Shan B and Lee W-H. . 1994 Mol. Cell. Biol. 14: 8166–8173.
Soucek T, Pusch O, Hengstschläger-Ottnad E, Adams PD and Hengstschläger M. . 1997 Oncogene 14: 2251–2257.
Strasser A, O'Conner L, Huang DCS, O'Reilly LA, Stanley ML, Bath ML, Adams JM, Cory S and Harris AW. . 1996 Behring Inst. Mitt. 97: 101–117.
Vairo G, Innes KM and Adams JM. . 1996 Oncogene 13: 1511–1519.
Wu X and Levine AJ. . 1994 Proc. Natl. Acad. Sci. USA 91: 3602–3606.
Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E and Dyson NJ. . 1996 Cell 85: 537–548.
Acknowledgements
The authors wish to thank T Littlewood and G Evans, M Eilers, PD Adams and C Borner for the generous gift of cell lines. We are grateful to T Soucek and K Braun for helpful discussion. Work in MHs laboratory is supported by the Austrian `Fonds zur Förderung der wissenschaftlichen Forschung' and by the `Hans and Blanca Moser Stiftung' of the Medical Faculty of the University of Vienna.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hengstschläger, M., Hölzl, G. & Hengstschläger-Ottnad, E. Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle. Oncogene 18, 843–848 (1999). https://doi.org/10.1038/sj.onc.1202342
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202342
Keywords
This article is cited by
-
Tuberin negatively affects BCL-2’s cell survival function
Amino Acids (2006)
-
BCL-xL and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases
Oncogene (2002)
-
Staurosporine-induced apoptosis of HPV positive and negative human cervical cancer cells from different points in the cell cycle
Cell Death & Differentiation (2001)